Antibiotic Resistance News
-
Vancomycin-Resistant Enterococci (VRE) in Healthcare Settings Discussed in New Online Video
The IAQ Video Network and Cochrane & Associates announced the release of their latest educational video today. Their newest production discusses vancomycin-resistant enterococci, commonly referred to as VRE, which are bacteria that can cause various healthcare-associated infections (HAIs). “In the CDC’s 2019 Antibiotic Resistance Threats in the United States report, VRE was ...
-
Infection Prevention through Clean Water: How Healthcare Facilities Can Mitigate Healthcare-Associated Infections from Water
Healthcare-associated infections or HAIs are infections people get while they are receiving health care for another condition. These infections can happen in all types of healthcare settings and are a significant cause of patient illness and death. According to the Centers for Disease Control and Prevention (CDC), 1 in 31 patients experience a healthcare-associated infection on any given day, ...
-
MicrobioSeq’s Plasmid Identification Service Boosts Microbial Characterization Research
MicrobioSeq is the microbial genomics division on behalf of CD Genomics, headquartered in New York, USA. CD Genomics is a genomics service company with a renowned reputation for providing reliable sequencing, genotyping, microarray, and bioinformatics services. The product manager is pleased to announce the launch of the Plasmid Identification service, thus helping researchers to efficiently ...
By CD Genomics
-
Lumen Bioscience Receives Broad Funding Support for Advancement of Antibiotic Alternative for Preventing Traveler’s Diarrhea
Lumen Bioscience, a clinical-stage biotechnology company developing biologic drugs for highly prevalent diseases, today announced several funding milestones supporting the development of its therapeutics to prevent serious diarrheal diseases. The first is a $5 million grant from the Bill & Melinda Gates Foundation for a second Phase 2 study of an improved anti-campylobacter therapeutic, ...
-
7 December 2022 - FDA/CDC highlight need for infection preventions
Particular support for decolonisation of pathogens which is the approach taken by its XF-73 Nasal programme Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, today reports on the publication of findings from the US Food and Drug Administration (FDA) and US Centers for ...
-
Lumen Bioscience Awarded $3.6 Million by U.S. Army to Advance Low-cost, Scalable Preventative for Antibiotic-Resistant Infections
Lumen Bioscience—a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases—today announced the receipt of a $3.6 million award from the Department of Defense (DoD) for advanced biomedical product development in support of Naval operations. The award from the Medical Technology Consortium (MTEC), a 501(c)(3) biomedical technology consortium ...
-
A project led by Vaxdyn receives funding from Next Generation EU Funds
The project “AMReady: Development and manufacturing of vaccines for alleviation and preparedness for anti-microbial resistance global health crisis”, to be executed in 2021-2024 with a total budget of 1.4 million euro has been awarded funding by the competitive program Lineas Estratégicas de Colaboración Público-Privada 2021 of the State Research Agency of the ...
-
Ondine’s photodisinfection kills ESKAPE pathogens
Canadian life sciences company, Ondine Biomedical Inc. (LON: OBI), this week presented an in vitro study at the World Anti-Microbial Resistance Congress, in Maryland, USA on the effectiveness of its photodisinfection technology against the group of highly infectious and antibiotic-resistant bacteria known as ESKAPE pathogens.[i] ESKAPE pathogens are the most virulent and dangerous pathogens ...
-
Candida auris and Infection Control Resources for Healthcare Facilities in Puerto Rico
Several years ago, the Centers for Disease Control and Prevention (CDC) announced it was establishing the Antibiotic Resistance Laboratory Network (AR Lab Network) in Puerto Rico and all 50 states. It was designed to help detect new forms of drug resistance as novel fungal threats emerge. Specifically mentioned in the announcement was Candida auris. CDC reported that this fungus poses a unique ...
-
Infection Control Resources for Candida auris and Other Superbugs
The Centers for Disease Control and Prevention (CDC) established the Antibiotic Resistance Laboratory Network (AR Lab Network) in all 50 states back in 2016. It was designed to help detect new forms of drug resistance from germs like bacteria and fungi that develop the ability to defeat the drugs that were designed to kill them. Drug resistance has become a growing concern, especially in ...
-
Accelerate Diagnostics Announces Launch Of Accelerate Arc Module and BC Kit
The Accelerate Arc System cuts hours of wait time and numerous manual steps to deliver Identification (ID) results Unlocks rapid microbial ID from positive blood cultures for the large installed base of MALDI system users Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an in-vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis, ...
-
Optimal Peptides of BOC Sciences Arouse Heated Discussions at TIDES USA 2022
BOC Sciences successfully participated in TIDES USA 2022 from May 9th to 12th, at Hynes Convention Center, Boston. During the four-day exhibition, experts from BOC Sciences and global visitors are engaged in heated discussions concerning novel advances in peptide and amino acid synthesis, discovery, design, and engineering. BOC Sciences has been preparing for the world's largest gathering of ...
By BOC Sciences
-
Chiricahua Community Health Centers, Inc., Launches STI Testing Program for Women with Same-Day Results
The Body Agency Collective, Visby Medical, Inc. and CCHCI observe National STD Awareness Month with women’s health initiative on US-Mexico border. CCHCI among first healthcare providers in the nation to adopt new handheld PCR technology to detect gonorrhea, chlamydia and trichomoniasis in a single visit. Chiricahua Community Health Centers, Inc. (CCHCI) today announced a collaboration ...
-
Seres Therapeutics Presents Microbiome Therapeutic Research at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 1, 2022-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced the presentation of preclinical data supporting further investigation of a rationally designed microbial consortium candidate (DE486) to prevent or treat gastrointestinal (GI) mucositis – a common and often painful complication of radiation and ...
-
OpGen Announces Publication of Results from Major Clinical Study Using Unyvero Hospitalized Pneumonia (HPN) Panel in the Lancet Respiratory Medicine
208 patients enrolled in a prospective, randomized, controlled, multicenter, interventional trial Unyvero reduced the use of inappropriate antibiotic therapy by 45%, shortened inappropriate antibiotic therapy by 39 hours, and reduced overall antibiotic therapy duration by 22.5% Unyvero results combined with antibiotic stewardship are efficient and safe in decreasing time on inappropriate ...
By OpGen, Inc.
-
Locus Biosciences Announces $35 Million Financing
Proceeds will support product development and expansion of in-house cGMP manufacturing capabilities Company anticipates initiating Phase 2 trial of CRISPR-Cas3-enhanced bacteriophage precision medicine for UTIs mid-2022 Locus Biosciences, Inc. (“Locus”), a clinical-stage biotechnology company developing a new class of precision engineered bacteriophage treatments for a diverse ...
-
Seres Therapeutics Presents Preclinical Research on Investigational Microbiome Therapeutic SER-155 at the 2022 European Bone Marrow Transplantation Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 18, 2022-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, will present preclinical findings tomorrow at the European Bone Marrow Transplantation (EBMT) Annual Meeting that suggest SER-155 works by targeting the host immune response, potentially allowing patients undergoing hematopoietic stem cell transplantation (HSCT) ...
-
Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 4, 2022-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2022 financial results and provided business updates. “Seres continued to make important progress toward bringing SER-109 to patients suffering with recurrentC. difficileinfection (rCDI). Given the robust profile of SER-109 ...
-
OpGen’s Subsidiary Ares Genetics Commercially Launches New Sequencing and Analysis Services Globally
OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that its subsidiary, Ares Genetics (“Ares”), which strives to become a leader in bacterial genomics and AI-powered prediction of antimicrobial resistance (AMR), is commercially launching a series ...
By OpGen, Inc.
-
Lumen Bioscience Announces Publication in Nature Biotechnology Detailing Spirulina-Based Platform for Ultra-Large-Scale Production of Therapeutic Proteins
Researchers describe rapid, low-cost drug development approach Paper also reports preclinical and early clinical data for LMN-101 A common food source has been converted into a biomanufacturing platform that offers a way to rapidly produce mass quantities of biologic drugs for common diseases that currently lack effective treatments. Researchers at Lumen Bioscience report in Nature ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you